EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
SLD Summit 202626-28 February, Budapest
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PO2 | MASLD or MetALD? Unveiling the Role of Alcohol in Liver Disease Progression in Diabetic Patients | Ermina Stratina |  Received |
 |
|||
| 1-PO1 | Cardiometabolic Stratification Reveals Heterogeneous Hepatocellular Carcinoma Risk in MASLD with Advanced Fibrosis | Mario Romeo | Received |
|
|||
| 4-PT2 | The chronic exposure to Bisphenol A influences trained immunity and induces immunometabolic innate cells reprogramming, promoting metabolic dysfunction associated steatotic liver disease progression | Mario Romeo | Received |
|
|||
| 4-PO3 | The Potential Role of A gut hormone Expression in MASLD Patients | Abdel Ghani Badran | Received |
|
|||
| 5-PO1 | The Potential Role of Resistin, Interleukin-6, and NT-proBNP in the Development of Cardiac Disease among Patients with Type 2 Diabetes Mellitus | Mohamed Abdel-Samiee | Received |
|
|||
| 5-PO7 | The influence of coagulation homeostasis disorders on the development of obstetric complications in pregnant women with metabolic-associated steatohepatitis and dyslipidemia | Lina Bahniy | Received |
|
|||
| 7-PO7 | Combined effect of Atorvastatin and Ambrisentan on the hemodynamic alterations and liver fibrosis in a translational rat model of MASLD with advanced fibrosis | M Serra Cusidó | Received |
|
|||
| 8-PO8 | Biomarkers of cardiometabolic risks for disease severity prediction in metabolic dysfunction-associated steatotic liver disease patients | Jee-Fu Huang | Received |
|
|||
| 9-PO5 | Arterial stiffness in patients with metabolic dysfunction-associated steatotic liver disease | Adelaida Solomon | Received |
|
|||
| 9-PO6 | Attenuation versus backscatter for the non-invasive quantification of hepatic steatosis in metabolic dysfunction–associated steatotic liver disease | Silvia Andaloro | Received |
|
|||
| 10-PO2 | Circulating Mir-122, Mir-34a, and Mir-99a as Potential Predictive Biomarkers of Metabolic Dysfunction-Associated Steatotic Liver Disease | Mohamed Abdel-Samiee | Received |
|
|||
| 11-PO3 | Long-term intake of Bicarbonate-Sulfate-Calcium-Magnesium mineral water improves MASLD-related outcomes by modulating intestinal permeability, systemic inflammation, and oxidative stress | Mario Romeo | Received |
|
|||
| 11-PO2 | Depression, Anxiety, and Comorbidities as Key Factors Associated with Fatigue in MASLD: Insights from a Nationwide Study | Anna Sheptulina | Received |
|
|||
| 12-PO4 | MPEP attenuates hepatic steatosis via mGluR5/PKC inhibition and AMPK activation in hepatocytes and liver organoids | Michelangelo Trucchi | Received |
|
|||
| 12-PO7 | Efficacy of luseogliflozin in elderly patients with type 2 diabetes and metabolic dysfunction associated steatotic liver disease | Tomonori Fujishima | Received |
|
|||
| 12-PO8 | Transcriptional Dysregulation of Hepatocyte-Specific Factors inChronic Liver Disease: A Potential Biomarker Panel | Sandip Todkar | Received |
|
|||
| 12-PO1 | Comparative evaluation of MAFLD versus MASLD diagnostic criteria for predicting de novo hepatocellular carcinoma risk in HCV-infected individuals following sustained virological response | Mario Romeo | Received |
|
|||
| 13-PO7 | Aldafermin as a promising therapy for metabolic dysfunction–associated steatotic liver disease: evidence from a meta-analysis of randomized trials | Ali Othman | Received |
|
|||
| 14-PO4 | Association Between Neck Circumference and Steatotic Liver Disease: A Systematic Review and Meta-analysis | Cecilia Katzenstein | Received |
|
|||
| 14-PO2 | Evaluating alanine aminotransferase as a screening marker for steatotic liver disease in HIV-positive and general populations: A cross-sectional study from Egypt | Heba Abdelmalik | Received |
|
|||
| 15-PO5 | Detarminants of long-term remnant liver donor fibroprogression | Devapriya Manazhy | Received |
|
|||
| 15-PO4 | Liver steatosis predictors in liver cirrhosis with or without ascites. | Corina Pietrareanu | Received |
|
|||
| 15-PO6 | Obesity – Factor of hepatocarcinogenesis in chronic Hepatitis C | MARILENA STOIAN | Received |
|
|||
SLD Summit 2026
26-28 February, Budapest
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 26/02/2026 TO 26/02/2026
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 17/02/2026
|
|
